Rosa Blanco is Laboratory Senior Technician (1993) and Anatomy and Cytology
specialist (1996) by the IES Cantabria. Since then, her extensive career has been focused
on laboratory work in theUniversity of Cantabria (1997-2001, 2003-2013), the
Hematology Service of University Hospital Marqués de Valdecilla (2002) and The
Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC) (2013-2018, 2020-
present). Thanks to this experience, she is author of numerous scientific articles and she
is ambassador of the Spanish Association for Cancer Research (ASEICA).
With an entrepreneurial spirit, Rosa co-founded the biotechnology company StemVital in
2015, first UCEm prize winner, among recognitions. Also, she was awarded the prize for
the entrepreneurial woman in the IV edition of the Cantabria 2019 entrepreneurial awards.
Since 2020, she is lab manager at IBBTEC in the Genomic Analysis of Tumour
Development research group.
Genomic analysis of tumour development group
Research lines
- Role of chromatin remodeling genes in cancer development.
- Use of next-generation sequencing technologies for the identification of new molecular mechanisms of cancer initiation, progression and metastasis.
- Characterization of the role of intratumor heterogeneity in cancer progression
Funding
- Plan Nacional I+D+I (2012), Investigación Fundamental No Orientada. "Caracterización molecular del papel de los complejos remodeladores de cromatina en el desarrollo tumoral" SAF2012-31627 IP: Ignacio Varela
- Fundación Ramón Areces (2014), Ayudas a la investigación en Ciencias de la Vida y la Materia. "Caracterización molecular del papel de la disfunción mitocondrial en el desarrollo tumoral". IP: Ignacio Varela
- European Research Council (2014). Starting Grant. "Molecular Characterization of the role of intratumor heterogeneity in cancer progression and metastasis". IP: Ignacio Varela
- Plan Nacional I+D+I (2016), Proyectos RETOS . "Molecular study of the mechanisms of SWI/SNF complexes in tumour progression and their potential exploitation for cancer therapy." SAF2016-76758-R IP: Ignacio Varela
